REPL

19.0700.83%
SP

Sushil Patel

CEO & Director

Dr. Sushil Patel, also known as Sush, Ph.D., is Independent Director of Revolution Medicines, Inc. from June 16, 2022. Dr. Patel is CEO & Director of Replimune Group, Inc. from April 1, 2024. Dr. Patel served as the Chief Commercial Officer at Replimune Group, Inc. since May 3, 2021 and serves as its Chief Strategy Officer. He served as the Head of global oncology for lung cancer, skin cancer and rare / agnostic tumor types at Genentech, a member of the Roche Group. He was previously lifecycle leader and “CEO for the molecule” in lung cancer for the multi-billion-dollar checkpoint blockade drug Tecentriq. He has a wealth of experience in immuno-oncology and an incredible track record of success in defining and implementing launch strategies. He also has oncology experience with pertinent skills in strategy, US and international oncology marketing and sales and clinical development. He most recently served as Franchise Head in Global Product Strategy for Genentech. Prior to his career in biotechnology, he worked as a strategic management consultant and at IMS Health in their Pharma Strategy Group. He received a Doctor of Philosophy in Molecular Biology and a Master of Sciences in Biotechnology, both from the Imperial College of Science Technology in 1993 and Medicine, University of London in 1999. He has B.S. in Microbiology and Microbial Technology from the University of Warwick in 1992.

Positions